Jefferies Group Reiterates “Hold” Rating for Victrex (VCT)
Victrex (LON:VCT)‘s stock had its “hold” rating reaffirmed by equities researchers at Jefferies Group in a research report issued on Tuesday, StockRatingsNetwork.com reports. They currently have a GBX 1,760 ($28.24) price target on the stock. Jefferies Group’s price target would indicate a potential upside of 12.53% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Victrex in a research note to investors on Thursday, October 3rd. They now have a GBX 1,860 ($29.84) price target on the stock. Separately, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex in a research note to investors on Monday, September 30th. They now have a GBX 1,400 ($22.46) price target on the stock. Finally, analysts at Bank of America Corp. reiterated an “underperform” rating on shares of Victrex in a research note to investors on Monday, September 9th. They now have a GBX 1,400 ($22.46) price target on the stock. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company’s stock. Victrex has a consensus rating of “Hold” and a consensus target price of GBX 1,661.54 ($26.66).
Victrex (LON:VCT) opened at 1586.00 on Tuesday. Victrex has a 52-week low of GBX 1364.00 and a 52-week high of GBX 1791.00. The stock has a 50-day moving average of GBX 1593. and a 200-day moving average of GBX 1609.. The company’s market cap is £1.335 billion.
Victrex plc is engaged in the manufacturing and selling of high performance polymers. The Company’s business is organized as two business units: Victrex Polymer Solutions (LON:VCT) and Invibio Biomaterial Solutions (Invibio).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.